By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced a contract with Japanese drug firm Eisai to provide biomarker services for Alzheimer's disease.

Under the terms of the deal, Proteome Sciences, based in Surrey, UK, will measure candidate biomarkers for AD using its AD-TMT-SRM assay set on human samples, it said in a statement.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.